Affordable Access

Access to the full text

The reproducibility and prognostic value of serial measurements of heart rate response to regadenoson during myocardial perfusion imaging

Authors
  • Andrikopoulou, Efstathia1, 2
  • AlJaroudi, Wael A.3
  • Farag, Ayman1
  • Lester, Davis1
  • Patel, Hiren1
  • Iskandrian, Ami E.1
  • Hage, Fadi G.1, 2, 4
  • 1 University of Alabama at Birmingham, Division of Cardiovascular Disease, Department of Medicine, Birmingham, AL, USA , Birmingham (United States)
  • 2 Section of Cardiology, Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA , Birmingham (United States)
  • 3 Clemenceau Medical Center, Division of Cardiovascular Medicine, Beirut, Lebanon , Beirut (Lebanon)
  • 4 University of Alabama at Birmingham, Lyons Harrison Research Building 306, 1720 2nd AVE S, Birmingham, AL, 35294, USA , Birmingham (United States)
Type
Published Article
Journal
European Journal of Nuclear Medicine
Publisher
Springer-Verlag
Publication Date
Apr 15, 2016
Volume
43
Issue
8
Pages
1493–1502
Identifiers
DOI: 10.1007/s00259-016-3380-y
Source
Springer Nature
Keywords
License
Yellow

Abstract

PurposeThe heart rate response (HRR, percentage change from baseline) to regadenoson during myocardial perfusion imaging (MPI) can provide incremental prognostic value in patients with known or suspected coronary artery disease. Our purpose was to evaluate the variability and prognostic value of HRR on serial measurements.MethodsWe studied 648 consecutive patients (61 ± 11 years, 48 % with diabetes) who underwent two regadenoson MPI studies (16 ± 9 months between studies). HRR <30 % was defined as abnormal. All-cause mortality was determined by chart review and verified using the US Social Security Death Master File.ResultsHRR was well correlated between the two studies (intraclass correlation coefficient 0.72, 95 % CI 0.67 – 0.76) with no systematic bias (mean difference 0.88 %, p = 0.2) or proportional bias (p = 0.5) by Bland-Altman analysis in all patients and in those with normal MPI on both studies. Of the 308 patients (48 %) with normal baseline HRR (HRR-1), 33 % had developed a blunted HRR on the second MPI study (HRR-2). Older age, male gender, end-stage renal disease, and abnormal baseline left ventricular ejection fraction were independent predictors of a new-onset abnormal HRR. During a mean follow-up of 2.4 ± 1.2 years, 55 patients (8.5 %) died. Patients with a blunted HRR-1 had increased mortality risk irrespective of their HRR-2 (p = 0.9, log-rank test). Among patients with normal HRR-1, a blunted HRR-2 was an independent predictor of all-cause mortality beyond clinical and traditional MPI data (hazard ratio 2.83, 95 % CI 1.14 – 7.03). Finally, patients with a normal HRR-1 and HRR-2 had the lowest event rate, while those with any abnormal HRR had an increased risk of death (hazard ratio 2.5, 95 % CI 1.2 – 5.4).ConclusionThere was good correlation in the HRR to regadenoson on serial measurements without systematic or proportional biases. Patients with consistently normal HRR had the best prognosis.

Report this publication

Statistics

Seen <100 times